09.25.25 -- Green Is The New KPI: Sustainability In Pharma Outsourcing

Explore 20+ new CDMO presenters in quick 20-minute sessions during Outsourced Pharma’s October Partner Week. Sessions include Analytical Services, ADC, Large and Small Molecules, Cell and Gene Therapy, and Fill/Finish. Each session offers a quick, informative look at capabilities to help you find the best-fit partner. Registration, on-demand access, and interactive Q&A are all free.

Gain valuable knowledge on addressing formulation stability, improving product shelf life, and enhancing overall product performance in biopharmaceutical studies.

As drug sponsors continue to navigate increasing global demand for complex biologics, it is vital to assess which outsourcing strategies mitigate risk while maintaining budgets and timelines.

Antibody-drug conjugates' manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill and finish.

Modern analytical tools produce more data than we know what do with. Artificial intelligence helps condense, interpret, and utilize what's most meaningful.

By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.

Delivering high viscosity (HV) formulations with a truly human solution involves a balance between safety and practicality. Learn the importance of achieving this solution with HV autoinjector design.

Discover how high-speed isolator lines enable sterile, scalable manufacturing for complex biologics and injectables with unmatched efficiency and product integrity.

Utilizing expert analytical testing services can unlock the potential of biosimilars and bring cost-effective treatments to market faster.

Unlock the full potential of your ADCs with a site-specific conjugation platform that delivers unmatched stability, homogeneity, and therapeutic performance.

Eurofins CDMO Alphora consolidates ADC development and manufacturing under one roof, streamlining processes, enhancing safety, and accelerating delivery of high-quality, clinically-ready ADCs.

Corvus, a small biotech developing precision medicines, primarily for oncology patients, was seeking to develop a monoclonal antibody called CPI06, now known as Mupadolimab.

A stability program evaluates how pharmaceutical and biologic products maintain potency, purity, and quality over time, which ensures safety, effectiveness, and regulatory compliance.

By using our proprietary non-viral gene insertion technology, GPEx Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.